Overview

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The study aims to investigate and compare the effect of Mirabegron (YM178) on subjects with mild and moderate hepatic impairment compared to healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron